CRISPR Therapeutics Uses HIVE
CRISPR Therapeutics, global leader in gene editing therapies, uses HIVE as its in-house bioinformatics platform for a wide variety of uses, such as assay quality control, alignment, classification and target discovery amongst others.
CRISPR Therapeutics applies its gene editing technology to treat hemoglobinopathies, cancer, diabetes and other diseases.
Cutting Edge Gene Editing
CRISPR Therapeutics, a global leader in gene editing therapies, was co-founded by Dr. Emmanuelle Charpentier, the co-inventor of the CRISPR/Cas9 gene editing technique and recipient of the 2020 Nobel Prize in Chemistry.